Urovant Sciences, Inc

Targeted Therapy Technologies, LLC, based in Irvine, CA, specializes in the design and development of episcleral systems aimed at restoring vision through better and less invasive therapies. The company operates under stringent good manufacturing practices (cGMP) and utilizes medical-grade biocompatible materials for its ophthalmic applications. 3T's in-house manufacturing and quality laboratories are equipped to ensure the formulation and optimization of episcleral sustained release formulations, supporting clinical supplies for phase I testing. The company emphasizes precise formulation methods that minimize waste and active pharmaceutical ingredient requirements, while maintaining rigorous testing and control for all manufactured products. Generated from the website

Central Admixture Pharmacy Services (CAPS) is the largest network of outsourcing admixture pharmacies in the United States, offering high-quality compounding services and solutions to hospitals and outpatient facilities nationwide. With over 30 years of experience, CAPS provides customized, patient-specific compounding needs through their 22 regional pharmacies and distributes non-patient-specific compounded sterile preparations through their FDA-registered outsourcing facilities. As a pioneer in the outsourcing of compounded sterile preparations, CAPS is committed to delivering confidence and ensuring patient safety by eliminating dual order entry and decreasing transcription errors. Their comprehensive compliance program, in accordance with the Compliance Program Guidance for Pharmaceutical Manufacturers, ensures the highest quality standards are met. CAPS also offers consulting, training, and educational services to further support their customers' needs.Generated from the website

AVANIR Pharmaceuticals is engaged in the research, discovery, development and licensing of innovative drug products used in the treatment of chronic diseases. Its product candidates address therapeutic markets that include the central nervous system, atherosclerosis, inflammatory diseases and infectious diseases. Its research and drug discovery programs are focused primarily on small molecules that can be taken orally as therapeutic treatments. The company's lead product candidate, Neurodex, is used for the treatment of Involuntary Emotional Expression Disorder, a condition also known as pseudobulbar affect or emotional lability. Also in clinical development is AVP 13358, a selective cytokine inhibitor. AVANIR was founded in 1988 and has corporate headquarters in San Diego. Its common shares trade on the NASDAQ under the ticker symbol AVNR.